In patients with metastatic colorectal cancer (CRC) treated with bevacizumab, expression level of CAIX, PI3K p110a, and MET in metastases did not predict objective response (OR). PTEN loss was associated with OR but not OS. Tumor heterogeneity should be taken into consideration [114]. The gene discussed is MET; the disease is metastatic colorectal cancer.